Overview |
bsm-30249A-PE-CY5 |
mouse CD40/PE-Cy5 |
FCM |
Mouse |
Specifications |
Unconjugated |
Rat |
Monoclonal |
4G6 |
IgG2a/Kappa |
n/a |
Affinity purified by Protein G |
0.01M PBS, 0.5%BSA, 0.03% Proclin300 |
Store at 2-8℃. Protect from light. Avoid freezing. |
Target |
21939 |
P27512 |
Tumor necrosis factor receptor superfamily, member 5; B cell associated molecule CD40; B cell surface antigen CD40; B cell-associated molecule; B-cell surface antigen CD40; Bp50; CD 40; CD40 antigen (TNF receptor superfamily member 5); CD40 antigen; CD40 molecule; CD40 molecule, TNF receptor superfamily member 5; CD40 protein; CD40 type II isoform; CD40L receptor; CDw40; GP39; HIGM1; IGM; IMD3; MGC9013; Nerve growth factor receptor related B lymphocyte activation molecule; p50 antibody T-BAM; TBAM; TNF receptor superfamily member 5; TNR5_MOUSE; TRAP antibody Tumor necrosis factor receptor superfamily member 5; Tumor necrosis factor receptor superfamily member 5 precursor; Tumor necrosis factor receptor superfamily, member 5, isoform CRA_a; AI326936. |
Predicted to enable antigen binding activity; protein domain specific binding activity; and ubiquitin protein ligase binding activity. Involved in B cell mediated immunity; CD40 signaling pathway; and cellular calcium ion homeostasis. Acts upstream of or within several processes, including defense response to other organism; positive regulation of B cell activation; and positive regulation of interleukin-12 production. Located in external side of plasma membrane and intracellular membrane-bounded organelle. Part of CD40 receptor complex. Is expressed in several structures, including alimentary system; brain; hemolymphoid system gland; liver and biliary system; and reproductive system. Human ortholog(s) of this gene implicated in several diseases, including Kawasaki disease; autoimmune disease (multiple); end stage renal disease; hyperimmunoglobulin syndrome (multiple); and non-Hodgkin lymphoma (multiple). Orthologous to human CD40 (CD40 molecule). [provided by Alliance of Genome Resources, Apr 2022] |
Application Dilution |
FCM |
1:20-100 |